Top

International Journal of Clinical Pharmacy

Published in:

Open Access 01-08-2018 | Commentary

Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology

Authors: Paolo Baldo, Sara Francescon, Giulia Fornasier

Published in: International Journal of Clinical Pharmacy | Issue 4/2018

Abstract

The terminology used in pharmacovigilance can cause confusion, because there are similar terms that describe different phenomena (e.g. adverse reactions, adverse drug reactions, and side effects). Incorrect use of terminology can have negative effects on the reporting of adverse drug reactions and on the interpretation of these reports. To explain the most common terms used in pharmacovigilance, this article first describes the pharmacovigilance workflow process in the European Union and, as an example, in Italy. Then, the article reviews common pharmacovigilance terms.

Palaian S, Ibrahim MI, Mishra P. Health professionals’ knowledge, attitude and practices towards pharmacovigilance in Nepal. Pharm Pract. 2011;9(4):228–35.

Steurbaut S, Hanssens Y. Pharmacovigilance: empowering healthcare professionals and patients. Int J Clin Pharm. 2014;36(5):859–62.CrossRef

Lindquist M. The need for definitions in pharmacovigilance. Drug Saf. 2007;30(10):825–30.CrossRef

Baldo P, Fornasier G, Francescon S, Ferrarin E, Truccolo I, De Paoli P. Toxicities and adverse drug reactions experienced during anticancer treatment: it is desirable to consider the problem within the international system of pharmacovigilance. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(25):2824–5.CrossRef

European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Module VI—collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c.

Agenzia Italiana del Farmaco (AIFA). Novità europee e italiane in tema di farmacovigilanza: Il New Eudravigilance System e il conseguente impatto a livello nazionale. http://www.agenziafarmaco.gov.it/content/la-legislazione-di-farmacovigilanza.

Agenzia Italiana del Farmaco (AIFA). La legislazione di farmacovigilanza [cited 2018 Jun 20]. http://www.aifa.gov.it/sites/default/files/2017-11-13_NewEV_versione_221117-2.pdf.

European Medicines Agency (EMA)—Pharmacovigilance. Monitoring of medical literature and entry of adverse reaction reports into EudraVigilance [cited 2018 Jun 7]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000633.jsp&mid=WC0b01ac05808ce84c.

ICH harmonised tripartite guideline. Post-approval safety data management: definitions and standards for expedited reporting e2d. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf.

10.

Baldo P, De Paoli P. Pharmacovigilance in oncology: evaluation of current practice and future perspectives. J Eval Clin Pract. 2014;20(5):559–69.CrossRef

11.

CIOMS. Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII. CIOMS, Geneva, 2010; p 14.

12.

EMA. Draft presentation: Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2012/05/WC500127919.pdf.

13.

European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Module IX—Signal management. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c.

14.

European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Module V—Risk management systems (Rev 2). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c.

15.

EU. Medicinal products in the European Union. http://www.europarl.europa.eu/RegData/etudes/IDAN/2015/554174/EPRS_IDA(2015)554174_EN.pdf.

16.

European Medicines Agency (EMA)—Pharmacovigilance. Good pharmacovigilance practices [cited 2018 Jun 7]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c.

17.

European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Module X—Additional monitoring. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c.

18.

Directive 2001/83/EC. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004481.pdf.

19.

Definition—World Health Organization. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/trainingcourses/definitions.pdf.

20.

ICH. Clinical safety data management: definitions and standards for expedited reporting. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.

21.

Guideline on good pharmacovigilance practices (GVP)—Annex I—Definitions (Rev 4). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c.

22.

Directive 2010/84/EU. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf.

23.

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.CrossRef

24.

MedDRA. 2018 [cited 2018 Jan 18]. https://www.meddra.org/.

25.

Common Terminology Criteria for Adverse Events (CTCAE)|Common Terminology Criteria for Adverse Events (CTCAE)|Protocol Development|CTEP. 2018 [cited 2018 Jan 18]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.

Title: Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology
Authors: Paolo Baldo
Sara Francescon
Giulia Fornasier
Publication date: 01-08-2018
Publisher: Springer International Publishing
Published in: International Journal of Clinical Pharmacy / Issue 4/2018
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-018-0711-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Prevalence and characteristics of hospital inpatients with reported fluoroquinolone allergy

Learning the effects of psychotropic drugs during pregnancy using real-world safety data: a paradigm shift toward modern pharmacovigilance

The role of the suspicious renal pharmacist in identifying unusual adverse drug reactions—why this is not a small problem

The role and strategy of ISoP in global pharmacovigilance

Pharmacovigilance in developing countries (part II): a path forward

Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page